Article

B + L recalls cannula + OVD

Bausch + Lomb (B + L) has issued a Class I recall of cannulas packed in sodium hyaluronate ophthalmic viscosurgical device (Amvisc).

 

Rochester, NY-Bausch + Lomb (B + L) has issued a Class I recall of cannulas packed in sodium hyaluronate ophthalmic viscosurgical device (OVD).

The recall includes certain lots of B + L 27G Sterile Cannula packed in either 1.2% sodium hyaluronate (Amvisc, Bausch + Lomb) (Model 59051, 59081, 59051L, 59081L) or 1.6 % sodium hyaluronate (Amvisc Plus, Bausch + Lomb) (Model 60081, 60051, 60051L, 60081L) OVD. Affected lot numbers are listed in the Recall Notice.

The cannulas may leak viscoelastic material or detach from the syringe during injection. In rare incidences, detachment has resulted in serious patient injury.

B + L is advising customers to discontinue use of the product and either destroy or quarantine it under refrigeration pending a sales representative visit to their site.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.

Read the MedWatch safety alert, including a link to the Recall Notice, at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm336466.htm.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
© 2025 MJH Life Sciences

All rights reserved.